Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Carsten Schwänen"'
Autor:
Sabine Kayser, Richard F. Schlenk, Delphine Lebon, Martin Carre, Katharina S. Götze, Friedrich Stölzel, Ana Berceanu, Kerstin Schäfer-Eckart, Pierre Peterlin, Yosr Hicheri, Ramy Rahme, Emmanuel Raffoux, Fatiha Chermat, Stefan W. Krause, Walter E. Aulitzky, Sophie Rigaudeau, Richard Noppeney, Celine Berthon, Martin Görner, Edgar Jost, Philippe Carassou, Ulrich Keller, Corentin Orvain, Thorsten Braun, Colombe Saillard, Ali Arar, Volker Kunzmann, Mathieu Wemeau, Maike de Wit, Dirk Niemann, Caroline Bonmati, Carsten Schwänen, Julie Abraham, Ahmad Aljijakli, Stephanie Haiat, Alwin Krämer, Albrecht Reichle, Martina Gnadler, Christophe Willekens, Karsten Spiekermann, Wolfgang Hiddemann, Carsten Müller-Tidow, Christian Thiede, Christoph Röllig, Hubert Serve, Martin Bornhäuser, Claudia D. Baldus, Eva Lengfelder, Pierre Fenaux, Uwe Platzbecker, Lionel Adès
Publikováno v:
Haematologica, Vol 106, Iss 12 (2021)
The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide and all-trans retinoic
Externí odkaz:
https://doaj.org/article/d1110d66d5bd4ca48add2308757b49eb
Autor:
Sabine Bode-Erdmann, Godehard Friedel, R. F. Falkenstern-Ge, Jörn Sträter, German Ott, Carsten Schwänen, Dina Mönch, Jörg Kalla, Siegfried Klumpp, Claudia Kalla
Publikováno v:
Oncotarget
Malignant pleural mesothelioma (MPM) is a neoplasm with inferior prognosis and notorious chemotherapeutic resistance. Targeting aberrantly overexpressed kinases to cure MPM is a promising therapeutic strategy. Here, we examined ALK, MET and mTOR as p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05ee8bae5d7cc2074fbb0de3e4f5f77d
https://doi.org/10.18632/oncotarget.25111
https://doi.org/10.18632/oncotarget.25111
Autor:
Hartmut Döhner, Verena I. Gaidzik, Jürgen Krauter, Michael Heuser, Michael Girschikofsky, Veronica Teleanu, Andrea Kündgen, Heinz-A. Horst, Arnold Ganser, Doris Kraemer, Bernd Hertenstein, Gerald Wulf, Mark Ringhoffer, Markus P. Radsak, Karin Mayer, Peter Paschka, Carsten Schwänen, Thomas Heinicke, Walter Fiedler, Elisabeth Lange, Axel Benner, Gudrun Göhring, Uwe M. Martens, Daniela Weber, Richard F. Schlenk, Gerhard Heil, Felicitas Thol, Lars Bullinger, Helmut R. Salih, Konstanze Döhner, Mridul Agrawal, Michael Pfreundschuh, Richard Greil, Michael Lübbert
Publikováno v:
Leukemia. 32(7)
In this phase Ib/IIa study (ClinicalTrials.gov Identifier: NCT00850382) of the German-Austrian AML Study Group (AMLSG) the multikinase inhibitor dasatinib was added to intensive induction and consolidation chemotherapy and administered as single agen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ab879672cb2a22b0cf5551dfc0cd440
https://pubmed.ncbi.nlm.nih.gov/29720733
https://pubmed.ncbi.nlm.nih.gov/29720733
Autor:
Carsten Müller-Tidow, Olga Grishina, Hans-Walter Lindemann, Melanie Boerries, Arnold Ganser, Hartmut Döhner, Andreas Neubauer, Carsten Schwänen, Gerhard Heil, Geoffroy Andrieux, Björn Hackanson, Michael Heuser, Jürgen Krauter, Michael Lübbert, Gabriele Greve, Dietmar Pfeifer, Pascal Schlosser, Helmut R. Salih, Nadja Blagitko-Dorfs
Publikováno v:
Blood. 132:3892-3892
Background: The therapeutic effect of DNA-hypomethylating agents (HMAs) in AML/MDS is discussed to be via its effects on aberrant gene silencing by reactivation (e.g. through promoter hypomethylation). While this has been broadly studied in cell line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9adb6dd28f1504558aff571e490115f1
https://doi.org/10.1182/blood-2018-99-118762
https://doi.org/10.1182/blood-2018-99-118762
Autor:
Katharina Götze, Claudia Schmoor, Sebastian Scholl, Martina Crysandt, Hans-Walter Lindemann, Valerie Hupfer, Michael Heuser, Andreas Neubauer, Arnold Ganser, Richard F. Schlenk, Olga Grishina, Ulrich Germing, Hartmut Döhner, Helmut R. Salih, Aristoteles Giagounidis, Carsten Müller-Tidow, Gabriele Ihorst, Jürgen Krauter, Michael Lübbert, Gesine Bug, Björn Hackanson, Carsten Schwänen
Publikováno v:
Blood. 132:720-720
Introduction In older patients (pts), host factors such as functional deficits, comorbidities and other age-related factors are increasingly recognized as predictors for outcome of leukemia treatment. Thus, prospective clinical trials increasingly im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c80ffe418aba16f6905039f14218bd36
https://doi.org/10.1182/blood-2018-99-115974
https://doi.org/10.1182/blood-2018-99-115974
Autor:
Stephan Stilgenbauer, Hartmut Döhner, Katrin Scherer, Alexander Kröber, Sonja Häbe, Dirk Winkler, Axel Benner, Andreas Bühler, Thorsten Zenz, Tina Denzel, Jennifer Edelmann, Carsten Schwänen
Publikováno v:
Blood. 112:3322-3329
The exact prognostic role of TP53 mutations (without 17p deletion) and any impact of the deletion without TP53 mutation in CLL are unclear. We studied 126 well-characterized CLL patients by direct sequencing and DHPLC to detect TP53 mutations (exons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba7af024fe61f7f9f44b1edbf6db5a17
https://doi.org/10.1182/blood-2008-04-154070
https://doi.org/10.1182/blood-2008-04-154070
Autor:
T Hecker, Gabriele Hübinger, W Rittgen, M Wölfle, Lothar Bergmann, T. Karakas, Carsten Schwänen
Publikováno v:
Leukemia. 16:2096-2105
Bendamustine is a novel cytostatic agent, with activity in non-Hodgkin's lymphomas including B-chronic lymphocytic leukemia (B-CLL). The knowledge about its mode of action, however, is still limited. Here, we investigated the in vitro ability of bend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea56c4156fb87f6781bf241dcc36aca6
https://doi.org/10.1038/sj.leu.2402651
https://doi.org/10.1038/sj.leu.2402651
Autor:
Roger-Fei Falkenstern-Ge, Carsten Schwänen, Dina Mönch, German Ott, Claudia Kalla, Godehard Friedel, Jörg Kalla, Sabine Bode-Erdmann, M Kimmich, Martin Kohlhäufl, Jörn Sträter
Publikováno v:
Cancer Research. 77:1224-1224
Introduction: Malignant pleural mesothelioma (MPM) is a neoplasm with inferior prognosis and notorious chemotherapeutic resistance. New treatment approaches may be based on specific inhibitors against kinases that are overexpressed in MPM, such as mT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0a365ae588fbe2a22babf30557ab741
https://doi.org/10.1158/1538-7445.am2017-1224
https://doi.org/10.1158/1538-7445.am2017-1224
Autor:
Daniel Schöndube, Michael Girschikofsky, Richard F. Schlenk, Elisabeth Lange, Gerhard Heil, Felicitas Thol, Frank Griesinger, Hartmut Döhner, Gerhard Held, Carsten Schwänen, David Nachbaur, Daniela Weber, Axel Benner, Peter Reimer, Volker Runde, Arnold Ganser, Heinz-August Horst, Bernd Hertenstein, Wolff Schmiegel, Thomas Südhoff, Thomas Kindler, Konstanze Döhner, Maria-Veronica Teleanu, Peter Brossart, Frauke Theis, Peter Paschka, Beate Schultheis, Mark Ringhoffer, Stephan Kremers, Martin Griesshammer, Walter Fiedler, Uwe M. Martens, Jürgen Krauter, Maike de Wit, Andrea Kündgen, Jörg Westermann, Helmut R. Salih, Hartmut Kirchner, Anja Münnich, Doris Kraemer, Richard Greil, Andreas L. Petzer, Michael Heuser, Hans-Juergen Salwender, Verena I. Gaidzik, Nadezda Basara, Jochen Greiner, Gerald Wulf, Elisabeth Koller, Katharina Goetze, Tanja Hesse, Holger Hebart, Michael Lübbert, Heinz Kirchen
Publikováno v:
Blood. 128:449-449
Background: Internal tandem duplications (ITD) in the receptor tyrosine kinase FLT3 occur in roughly 25% of younger adult patients (pts) with acute myeloid leukemia (AML). The multi-targeted kinase inhibitor midostaurin combined with intensive chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50a5bc9ef74d4cbb911177a7b31c5cb3
https://doi.org/10.1182/blood.v128.22.449.449
https://doi.org/10.1182/blood.v128.22.449.449
Publikováno v:
Oncology Research and Treatment. 23:318-324
SummaryBendamustine is a nitrogen mustard derivative, devel-oped in East Germany in the early 60s in search for new cytotoxic drugs belonging to the group of alkylating drugs. With regard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::048960c13d7ae5df726899d8e72bc33b
https://doi.org/10.1159/000027163
https://doi.org/10.1159/000027163